Seattle Genetics, Inc (NASDAQ:SGEN) Director Felix Baker purchased 281,963 shares of Seattle Genetics stock in a transaction dated Wednesday, June 4th. The stock was purchased at an average price of $34.86 per share, for a total transaction of $9,829,230.18. Following the transaction, the director now directly owns 76,997 shares of the company’s stock, valued at approximately $2,684,115. Seattle Genetics, Inc. (NASDAQ:SGEN) stock performance was -0.05% in last session and finished the day at $40.10. Traded volume was 741,406.00million shares in the last session and the average volume of the stock remained 1.20million shares. The beta of the stock remained 1.38. Seattle Genetics, Inc. (NASDAQ:SGEN) insider ownership is 1.40%.

Corcept Therapeutics Inc (NASDAQ:CORT) Director G Leonard Baker, Jr. purchased 103,386 shares of the stock on the open market in a transaction that occurred on Wednesday, June 11th. The stock was purchased at an average price of $2.32 per share, with a total value of $239,855.52. Following the completion of the transaction, the director now directly owns 578,389 shares in the company, valued at approximately $1,341,862. Corcept Therapeutics Incorporated (NASDAQ:CORT) rose 12.66 percent to $2.58 Thursday on volume of 647,131.00million shares. The intra-day range of the stock was $2.25 to $2.68. Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $260.31million.

Cytori Therapeutics Inc (NASDAQ:CYTX) Director David Rickey acquired 30,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, June 5th. The shares were purchased at an average price of $2.34 per share, for a total transaction of $70,200.00. Following the acquisition, the director now directly owns 15,819 shares of the company’s stock, valued at approximately $37,016. Cytori Therapeutics Inc. (USA) (NASDAQ:CYTX)’s stock on June 12, 2014 reported a decrease of -0.40% to the closing price of $2.48. Its fifty two weeks range is $2.00 -$3.93. The total market capitalization recorded $187.14million. The overall volume in the last trading session was 466,469.00million shares. In its share capital, CYTX has 79.53million outstanding shares.

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) (10% owner) REGALS CAPITAL MANAGEMENT LPRegals Fund LPSlager David Mark  purchased 2,252 shares of the company’s stock on the open market in a transaction that occurred on Friday, June 6th. The shares were purchased at an average price of $4.44 per share, for a total transaction of $9,999.00. On Thursday, shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) advanced 2.50% to close the day at $11.05. Company monthly performance is recorded as 19.33%. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) quarterly revenue growth is -3.75%.

Biota Pharmaceuticals Inc (NASDAQ:BOTA) CEO Russell H. Plumb purchased 32,031 shares of the stock on the open market in a transaction that occurred on Wednesday, June 11th. The shares were purchased at an average price of $2.99 per share, for a total transaction of $95,772.69. Following the acquisition, the chief executive officer now directly owns 127,579 shares of the company’s stock, valued at approximately $381,461. Biota Pharmaceuticals Inc (NASDAQ:BOTA) stock performance was -0.65% in last session and finished the day at $3.05. Traded volume was 104,572.00million shares in the last session and the average volume of the stock remained 180.24K shares. The beta of the stock remained 1.42. Biota Pharmaceuticals Inc (NASDAQ:BOTA) insider ownership is 15.42%.